Cell agglutination reagent comprising conjugates of antibody covalently bound to liposomes

ABSTRACT

A number of naturally occurring antibodies to human erythrocyte surface antigens are capable of combining with their specific antigens (for example, Rhesus factor), but are not capable of producing visible hemagglutination. Also, the sensitivity of many diagnostic methods, such as in human blood typing, depends upon cell agglutination. 
     The present invention provides liposome-protein conjugates, especially useful for hemagglutination assays, having an enhanced agglutination capacity with respect to antibody from which the conjugates are derived.

The invention described herein was made in the course of work under agrant or award from the Department of Health and Human Services.

This is a divisional of application Ser. No. 316,125, filed Oct. 29,1981, now U.S. Pat. No. 4,598,051 which was a continuation-in-part ofapplication U.S. Ser. No. 129,654, filed Mar. 12, 1980, now abandoned.

FIELD OF THE INVENTION

The present invention relates generally to liposome conjugates, and moreparticularly to liposome-protein conjugates which have an enhancedagglutination ability, can rapidly and sensitively agglutinate cellssuch as erythrocytes, lymphocytes, and leukocytes, and which are usefulin applications such as blood typing.

BACKGROUND OF THE INVENTION

Liposomes are now well recognized as useful for delivery of therapeuticagents, such as cytotoxic drugs or other macromolecules capable ofmodifying cell behaviour, to in vivo sites. For example, U.S. Pat. No.3,993,754, inventors Rahman, et al, issued Nov. 23, 1976, discloses animproved method for chemotherapy of malignant tumors in which anantitumor drug is encapsulated within liposomes and the liposomescontaining the encapsulated drug are injected into an animal or man.

It has been suggested that target, or in vivo site, specificity might beconferred on liposomes by their association with specific antibodies orlectins. Methods of associating antibodies with liposomes have beendescribed, and may be generally divided into two groups--nonspecificassociation and covalent attachment.

Nonspecific association appears to rely upon the affinity of the Fcportion of the antibody for the hydrophobic region of the lipid bilayer.However, nonspecific association appears incapable of associating morethan about 15-30 microgram per micromole of lipid. Also, nonspecificassociation has little practical value because the liposomes arerendered more permeable than their encapsulated contents and proteinaggregation is produced during formation of the nonspecificallyassociated liposome-protein.

Prior to preparation of the covalently attached protein ofcoupled-protein species described in U.S. patent application Ser. No.129,654, attempts to covalently attach protein to liposomes had beenunsatisfactory. For example, some of the prior attempts had involvedmodifications of the proteins which tended to denature the protein, andthus a substantial loss of biological activity had ensued. Otherattempts to covalently attach protein to liposomes had produced verysmall amounts of specific attachment.

By contrast, activated liposomes in accordance with U.S. patentapplication Ser. No. 129,654 are readily and efficiently covalentlybound to a variety of biologically active proteins with at least about40 microgram of protein per micromole of lipid. For example, use of theactivated liposomes has achieved coupling of up to about 200 microgramof F(ab')₂ per micromole of lipid; further, such coupledliposome-protein species were shown to have an improved hemagglutinatingtitre by comparison to the original, soluble antibody from which theywere derived.

Very recently, another efficient method for coupling protein toliposomes has reported coupling of up to 600 microgram of Fab' permicromole of phospholipid via a disulfide interchange reaction. Martin,et al., Biochemistry, 20, pages 4429-4238 (July, 1981).

Meanwhile, agglutination methods are known and useful for applicationssuch as blood typing. However, many such methods have had to beperformed indirectly, or have been of relatively low sensitivity. Forexample, the Coombs test is an indirect agglutination method in thesense that a secondary, or intermediate, antibody must be used. Further,detection of antibodies which do not produce positive agglutination(e.g. visible agglutination) when combined with their specific antigenshas presented difficulties in applications such as blood crossmatching.Such serologically "incomplete" antibodies are believed to be fullyfunctional bivalent IgG molecules, but they are unable to bridge twocells and hence do not produce positive agglutination.

SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide ahemagglutination reagent having an improved capacity to agglutinateerythrocytes.

It is a further object of the present invention to provide anagglutination method, useful for assaying erythrocyte antigens, which israpid and sensitive.

It is yet a further object that human erythrocyte surface antigens,which are not normally capable of producing visible hemagglutination,may be agglutinated and the clumps subject to detection.

In one aspect of the present invention, an agglutination method usefulfor assaying cell surface antigens comprises providing a quantity ofliposome-protein conjugates where the protein thereof supplies anantigen binding capacity for at least a majority of the liposome-proteinconjugates, contacting the liposome-protein conjugates withsubstantially unagglutinated cells to form a mixture, and examining themixture for cell agglutination. The liposome-protein conjugates have atleast about 40 micrograms of protein per micromole of lipid.

In another aspect of the present invention, a reagent, useful forhemagglutination, comprises liposome-protein conjugates having anantibody covalently bound to the liposomes and an antigen bindingcapacity for erythrocytes bearing a surface antigen for which theantibody is specific. The reagent has a hemagglutinating activity whichis improved with respect to the hemagglutination activity of theoriginal antibody from which the liposome-protein conjugates arederived.

The liposome-protein conjugates and method of the present inventionprovide considerably improved sensitivity for agglutination assays. Forexample, agglutination of erythrocytes by use of the liposome-proteinconjugates can occur in seconds with large, clearly visible agglutinatedclumps of cells. By contrast, agglutination assays using the original,soluble antibody typically require minutes to produce agglutinationvisible to the naked eye, and the clumps of cells are much smaller.Thus, the ability of liposome-protein conjugates in accordance with thepresent invention to produce larger, more visible clots suggests thepossibility of simple, visual spot tests which need not require specialoptical equipment for observation, and for use in a variety ofdiagnostic applications.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Broadly, one aspect of the present invention is a diagnostic methodwherein liposome-ligand conjugates are contacted with ligand-bindingmolecules to form a mixture, and the mixture is examined forcombinations, or interactions, between the liposome-ligand conjugatesand the ligand-binding molecules. The ligand-binding molecules arecarried by at least one surface, more preferably carried by a pluralityof surfaces defined by discrete particles, and most preferably carriedby cell surfaces. The ligand of the liposome-ligand species is in anamount of at least about 40 micrograms per micromole of lipid, andpreferably is a protein having an antigen binding capacity. For example,when the protein is an antibody and the ligand-binding molecules areantigens carried by cell surfaces, then the mixture examinationfollowing the contacting step typically includes determining cellagglutination mediated by combinations between the coupled antibody andimmunological partners, or specific antigens, carried on the cells.Where the ligand is protein, the conjugates will hereinafter sometimesbe referred to as liposome-protein conjugates.

The at least one surface carrying the ligand-binding molecules may be anatural multivalent antigen or may also be formed by inanimate,synthetic materials. For example, among suitable non-cellular materialsare polyacrylamide beads about 5-10 microns in diameter havingimmobilized, or covalently bound, immunoglobulin on the bead surfaces,which are commercially available from Bio-Rad Laboratories under thetrademark "Immunobead", and polystyrene spheres about 1 micron indiameter, which may be coupled along their surfaces with immunoglobulinsuch as IgG, commercially available from Covalent Technology Corp. underthe trademark "Covaspheres".

As used herein, ligand and ligand-binding molecules mean moieties whichcan interact specifically but non-covalently with each other. One typeof such moiety pairings is an antigen-antibody interaction, another is ahormone-receptor interaction, and yet another is a carbohydrate-lectininteraction.

Liposome-protein conjugates useful in accordance with the presentinvention may be prepared in various ways. For example, one suitablepreparation is via activated liposome precursors where the precursorliposomes, before being covalently bound, are activated by means of anoxidizing reagent. A modification of this preparation is wherein thelipid, such as gangliosides, is first oxidized and then formed into theprecursor liposomes. Another suitable preparation is via disulfidebonds, as described by Martin et al, supra.

In any event, it is necessary that the protein be then covalently boundto the liposomes precursors in an amount of at least about 40 microgramsper micromole of lipid. A suitable preparation and properties oflipsome-protein conjugates will now be more fully described.

Preparation of Liposome-Protein Conjugates Via Activated LiposomePrecursors

Activated liposomes may be prepared from starting vesicles which aregenerally characterized either as unilamellar vesicles or multilamellarvesicles. Either liposomal structure is suitable. A particularlypreferred preparation is by the reverse-phase evaporation vesicle (REV)method, which is disclosed by U.S. Pat. No. 4,235,871, as is describedin Proc. Natl. Acad. Sci. U.S.A., Volume 75, No. 9, pp. 4194-4198(1978), entitled "Procedure For Preparation of Liposomes With LargeInternal Aqueous Space And High Capture By Reverse-Phase Evaporation",Szoka, Jr. and Papahadjopoulos, which disclosures are incorporatedherein by reference.

As is known to the art, a wide variety of materials may be encapsulated,if desired, by the precursor liposomes. For example, the precursorliposomes can encapsulate cytotoxic drugs, can encapsulate nucleicacids, and can encapsulate various proteins.

In any event, the precursor liposomes suitable for the present inventionmay be formed from either phosphatidylglycerol (hereinafter alsoreferred to as "PG"), which has an oxidisable group at the polar headregion, as the sole lipid, or may be formed from a mixture of two ormore different lipids.

When formed from two or more different lipids, at least one of thelipids contains oxidisable groups, such as vicinal amino or vicinalhydroxyl groups, along the polar head region of the lipid molecule. Forexample, in the instance of vicinal amino groups, a glycolipid havinggalactosamine or glucosamine residue is a suitable oxidisable lipid.More usually, at least one of the lipids will have vicinal hydroxylgroups at the polar head region. Particularly preferred as one of thelipids (that is, the oxidisable lipid) in a lipid mixture are theglycolipids such as lactosyl ceramide, galactocerebroside, gangliosides,and trihexosyl ceramide, and the phospholipids, such asphosphatidylclycerol and phosphatidylinositol.

The amount of such lipids having oxidisable groups (generally hereinreferred to as "oxidisable lipids") may vary with respect to the totallipids forming the precursor liposomes; however, it is preferred thatthe mole percent of oxidisable lipids be in an amount of at least about10 mole percent with respect to a total of the mixture of lipids.

Particularly preferred amounts of oxidisable lipids with respect to thetotal lipids are illustrated by Table I, below.

                  TABLE I                                                         ______________________________________                                                          Mole of Oxidisable Lipid                                    Oxidisable Lipid  To Total Lipid Mixture                                      ______________________________________                                        Lactosylceramide  About 10                                                    Trihexosylceramide                                                                              About 10                                                    Galactocerebroside                                                                              About 20                                                    Phosphatidylglycerol                                                                            About 33-40                                                 Phosphatidylinositol                                                                            About 20                                                    Gangliosides      About 10                                                    ______________________________________                                    

The structures of the preferred oxidisable lipids are well known;however, for clarity FIG. 1, below, illustrates PG as representative ofthe general structures of the oxidisable lipids having the polar headregions and the region of non-polar tails. ##STR1##

FIG. 1 is generally representative of all of the lipids which may bemixed to form the precursor liposomes in defining the polar head regionand the non-polar tails. The FIG. 1 structure is more particularlygenerally representative of the oxidisable lipids which have vicinalhydroxyl groups at the polar head region thereof.

When a mixture of lipids, including the oxidisable lipid, is utilized toform the precursor liposomes, then the remaining lipid or lipids mayinclude any of the amphiphilic substances known to produce liposomes. Aparticularly preferred lipid for combination with the oxidisable lipidsis phosphatidylcholine (hereinafter also referred to as "PC"),sphingomyelin or mixtures thereof.

As is known, the above discussed mixtures of lipid molecules formprecursor liposomes with the lipid molecules being arranged in eitherone bimolecular layer (unilamellar) or a plurality of bimolecular layers(multilamellar). In any event, the most outward bimolecular layer formsan outer surface for the liposome. In an aqueous solution, the polarhead regions of the lipid molecules are exposed, or extend into, theaqueous system in a generally radially outward orientation with respectto the outer surface. The non-polar tails extend radially inwardly withrespect to the outer surface and form a substantially continuoushydrocarbon phase of the bimolecular layer. This substantiallycontinuous hydrocarbon phase is relatively impermeable, and acts toencapsulate the materials inside the precursor liposomes.

Nevertheless, some mixtures of lipids forming the precursor liposomesmay tend to be permeable to small molecules, and cholesterol is adesirable addition to some of these lipid mixture for reducing thepermeability of the precursor liposomes. The cholesterol tends toorientate within the bimolecular layer. Other components may be utilizedin place of cholesterol to reduce the liposome permeability. Forexample, a phosphatidylcholine having the fatty acid saturated aliphaticchain, or non-polar tails, of a length of 18 (rather than the usualunsaturated 16 to 18 carbon chain obtainable from egg yolks) may beutilized. However, when sphingomyelin is mixed with the oxidisablelipid, the precursor liposomes thereof are inherently quite impermeableto small molecules.

A solution of precursor liposomes may thus be provided as has beendescribed above. This solution is preferably a polar solution, such asan aqueous solution, but may also be a non-polar solution. The precursorliposomes are contacted with a sufficient amount of a relatively mildoxidizing reagent to produce activated liposomes. Where the lipids to beused for liposomes are in a non-polar solution, the oxidizing reagentmay be lead tetraacetate. In the preferred polar solution, the oxidizingreagent of the contacting step is a periodate reagent, usually sodiumperiodate, which cleaves the vicinal amino or hydroxyl groups at thepolar head regions of the oxidisable lipids.

Where the solution is polar and the oxidizing agent is a periodatereagent, the pH and osmolarity of the liposome solution and an addedamount of periodate reagent should be substantially the same. The pH istypically about 6.0 to about 8.5. The oxidizing reagent producesactivated liposomes by oxidizing the oxidisable groups, such as thevicinal hydroxyl or amino groups of the oxidisable lipid, to yieldaldehyde moieties at the polar head regions of the oxidisable lipids. Asufficient quantity of periodate reagent will usually be a molar ratiowith respect to the total of lipid molecules of from about 1.5:1 toabout 6:1. The oxidation reaction of the contacting step is typicallyleft to proceed for about one-half hour at room temperature, althoughthe reaction may be permitted to proceed for up to about one hour onice. The periodate reagent is then preferably removed by gel filtrationthrough a column of dextran polymeric beads having an exclusion limit ofabout 75.000 daltons.

Reaction Schemes I, II and III diagrammatically illustrate theactivation of precursor liposomes, with the oxidisable lipids beingphosphatidylglycerol, phosphatidylinositol and lactosylceramiderespectively. ##STR2## Substantially all of the material which isinterior the outer surfaces of the activated liposomes remainsencapsulated during the above-described oxidation with periodatereagent. As illustrated by Reaction Schemes I-III, the aldehyde moietieswhich are formed by the oxidation, or modification, of the oxidisablelipids at the polar head regions thereof define covalent binding sitesfor the protein to be bound, or coupled.

A wide variety of proteins may be attached, or coupled, to the activatedliposomes. The mechanism of coupling is believed to occur between theprimary or secondary amino group along the protein and the aldehydemoiety of the activated liposomes so as to form a Schiff-base, forexample, with the primary amino group of a lysyl moiety. Such amechanism is diagrammatically represented by Reaction Scheme IV, whichfor simplicity illustrates only the terminal galactose (aftermodification) of lactosylceramide. ##STR3##

The coupling is driven to completion by a mild reducing agent,preferably sodium cyanoborohydride, so that a stable, covalent bond isformed between the protein and the activated liposome. For example,addition of a sufficient amount of sodium cyanoborohydride drives theSchiff-base of reaction Scheme IV, above, to completion, as is generallyillustrated by Reaction Scheme V, below. ##STR4## Reaction Schemes IVand V, above, diagrammatically illustrate coupling of a protein withlactosylceramide, where the lactosylceramide has been modified byoxidation to include aldehyde moieties. Use of the other oxidisablelipids proceeds by an analogous manner. In the instance of modifiedlactosylceramide, the secondary amine moiety which is covalently bindingthe protein to the activated liposome may further proceed, in thepresence of sodium cyanoborohydride, into an even more stable, tertiaryamine form.

Although sodium cyanoborohydride is the preferred reducing agent forcoupling proteins to the activated liposomes, other reducing agents maybe utilized, depending upon the particular circumstances. For example,borohydride may be utilized; however, the coupling reaction wouldusually then be conducted at a relatively alkaline pH, which may tend todenature the protein being coupled.

Suitable proteins for adequate coupling will have at least one primaryor secondary amino group, and preferably a plurality of primary orsecondary groups. Proteins having at least about 20 lysyl moieties permolecule are more preferred. IgG, with about 60 lysyl moieties, has beenfound to be particularly well coupled; another preferred antibody forcoupling with the activated liposome is F[ab']₂.

Four aqueous solutions of liposome, each containing from about 10 toabout 40 micromoles of lipid per mililiter, were activated as previouslydescribed. The precursor liposomes had been prepared by the REVprocedure and had been extruded through a polycarbonate filter to yieldliposomes having a diameter of about 0.2 micron. The solutions werebuffered at a pH of from about 6.0 to about 8.5. A fifth liposomesolution, wherein the oxidisable lipid was not oxidized, was prepared asa control. These four activated liposome solutions in accordance withthe present invention and the fifth control solution were as illustratedby Table II.

                  TABLE II                                                        ______________________________________                                        Solution                                                                             Lipid Composition Total Lipid                                                                              Vol.                                      No.    Molar Ratio       (micromole)                                                                              (ml.)                                     ______________________________________                                        1      PC/Lactosylceramide, 10:1                                                                       9.21       2.8                                       2      PC/Trihexosylceramide, 10:1                                                                     16.44      4.5                                       3      PC/PG, 1:1        9.5        3.1                                       4      Galactocerebroside/                                                                             15         0.6                                              PC/Cholesterol, 2:4:5                                                   5*    PC/Lactosylceramide, 10:1                                                                       7.11       2.8                                       ______________________________________                                         *Control solution, liposomes not activated                               

The five solutions as in Table II were treated as follows. 5 to 10milligrams of IgG in the same buffer as the liposome solutions wereadded to the respective liposome solutions (the activated liposomes weresuspended in the solutions with substantially no clumping). Sufficientsodium cyanoborohydride was added to give a concentration of about 20millimolar, and the solutions were left for about 2 to about 3 hours atroom temperature. The liposomes having covalently bound IgG thereon werethen purified by conventional methods, such as column gel filtration orcentrifugation. The amount of coupling is illustrated by Table III,below (the number of molecules per vesicle was estimated on theassumption that the vesicles were 0.2 micron in diameter, with about1.8×10¹² vesicles/micromole lipid).

                  TABLE III                                                       ______________________________________                                        Liposome                                                                             IgG (mg) Protein:Lipid Ratio                                                                             Molecules                                   Solution                                                                             added    (μg/mole)                                                                             (μg/mg lipid)                                                                       IgG/vesicle                               ______________________________________                                        1      20       112        147      251                                       2      14       57         75       128                                       3      14       47         62       106                                       4      10       96         126      216                                        5*    20       11         14        25                                       ______________________________________                                         *Control solution, liposomes not activated.                              

Binding of Protein to Liposomes

IgG coupling to activated liposomes has typically resulted in thebinding of from about 50 to about 200 micrograms of IgG per micromole oflipid. Substantially no coupling is observed in control liposomes.Nonspecific binding of proteins to activated liposomes was below thelimits of the protein assay utilized in determining coupling.

The proteins which may be covalently bound, or coupled, to the activatedliposomes retain a significant amount of biological activity. This isillustrated by use of immunopurified rabbit and antifluoresceinantibody, as follows.

Antifluorescein IgG binds specifically to fluorescein isothiocyanate andcarboxyfluorescein. Upon binding to the antibody, the fluorescence ofthe fluorescein is abolished, and this was used to measure the bindingactivity of the antibody. Successive additions of antibody to a solutionof carboxyfluorescein reduced the fluorescence due to quenching of thefluorophore upon binding to the antibody. The antigen binding capacityof liposome-bound antibody was compared by correlating the percentagereduction in fluorescence for a variety of specified proteinconcentrations in linear ranges where quenching was proportional to theprotein concentration as illustrated by Table IV, below (wherein theoriginal antibody, or control, linear range was from about 78/1 to about30/4; unbound antibody was from about 85/1 to about 40/5; and coupledantibody-activated liposomes was linear over the entire rangeillustrated).

                  TABLE IV                                                        ______________________________________                                        Fluorescent Intensity/Antibody conc. × 10.sup.8 (μmole/ml)           Original Antibody         Coupled Antibody-                                   (Control)   Unbound Antibody                                                                            Activated Liposome                                  ______________________________________                                        78/1        85/1          95/1                                                60/2        75/2          90/2                                                40/3        62/3          85/3                                                30/4        50/4          78/4                                                18/5        40/5          70/5                                                12/6        35/6          65/6                                                 8/7        30/7          60/7                                                 8/8        20/8          58/8                                                            15/9          50/9                                                ______________________________________                                    

As illustrated by Table IV, above, the fluorescent quenching ofcarboxylfluorescein by the original antibody preparation (control) andthe antibody that was recovered from the coupling process may becompared to antibody bound to the activated liposomes. If the activityof the original, control preparation is set at 100%, then the activityof the activated liposome bound antibody is about 33%, and of therecovered antibody is about 70%. Antigen binding capacity is, therefore,only partially inhibited by the inventive coupling process, and thecoupled protein displays, or retains, a significant amount of antigenbinding capacity.

Hemagglutination

Liposome-protein conjugates in accordance with the present inventionhave the ability to agglutinate erythrocytes. Activated liposomes,prepared as described above, were conjugated with antigen-antibody, andincubated with erythrocytes conjugated with fluorescein-isothiocyanate.This resulted in the agglutination of the erythrocytes and thehemagglutinating titre (expressed as the minimum concentration observedto cause agglutination) was improved by a factor of about 1.5 withrespect to the original, soluble antibody from which theliposome-protein conjugates were derivjed. Lower values of thehemagglutinating titre indicate more effective agglutination capacity.This is illustrated by Table V, below.

                  TABLE V                                                         ______________________________________                                        Hemagglutination of FITC-Human Erythrocytes                                   by Rabbit Antifluorescein IgG                                                 Preparation       Titre (microgram/ml)                                        ______________________________________                                        Liposomes Bound Antibody                                                                        1.22                                                        (500 molecules/vesicle)                                                       Untreated Antibody                                                                              1.92                                                        ______________________________________                                    

The improved ability of liposome-protein conjugates in accordance withthe present invention to agglutinate erythrocytes is also demonstratedin another preparation of liposome-protein conjugates via the activatedliposome precursors, as follows.

10 mg of F[ab']₂ was added to 10 μmole of vesicle lipid (after oxidationand desalting) in 1 ml of borateasline (pH 8.4), and then added 10 μl of1M sodium cyanoborohydride. After 18 hours at room temperature, thevesicles were separated from unbound protein by flotation ondiscontinuous dextran gradients (0 to 20 percent, weight to volume). Forquantitation of binding to cells the vesicles contained ³ H-labeleddipalmitoylphosphatidylcholine (DPPC; 10 μCi/μmole) and ¹⁴ C-labeledsucrose (1 μCi/μmole). "Targeted" vesicles were those having coupledrabbit F[ab']₂ to human erythrocytes, whereas "control" vesicles werecoupled to F[ab']₂ prepared from rabbit gamma globulin by pepsindigestion and absorption to a Staphylococcus aureus suspension.

The targeted vesicles and the control vesicles were then separatelyincubated with 10⁶ to 10⁸ human erythrocytes in 0.2 ml ofphosphate-buffered saline (PBS) at pH 7.4 for 1 hour at 37° C. Cellswere washed to remove unbound vesicles and were either taken up directlyin 10 ml of Triton-toluene scintillant and counted for [³ H]DPPC (10⁶ to10⁷ cells) or extracted after washing 10⁸ cells; the chloroform phasewas evaporated and counted for [³ H]DPPC content, and the aqueous phasewas incubated overnight at 60° C. to remove methanol and counted for [¹⁴C]sucrose content.

When vesicles (with from about 1 to 500 nmoles of lipid) were incubatedwith 10⁸ cells there was a marked difference between targeted andcontrol binding, with 80% of the vesicles binding at about 20 to 500μmole of lipid. Control binding with vesicles conjugated to nonspecificF[ab']₂ was very low (<1 percent) and did not appreciably increasebetween 100 and 500 nmole of lipid). Both the vesicle lipids and theencapsulated sucrose bound to the cells in nearly identical proportions,indicating that cell binding caused no loss of vesicle contents and thatthe antibody-conjugated liposome preparation was reasonably homogeneouswith respect to lipid, encapsulating aqueous marker, and antibody. Whenvesicles were incubated with 10⁷ erythrocytes there was a markeddifference in binding between the targeted and non-targeted samples.Although a small fraction of the total available vesicles became bound,the number of vesciles that bound to each cell was increased. Vesiclesincubated with 10⁶ cells also exhibited binding specificity (not shown),with 6 nmole of specific antibody-bearing vesicles and 2 nmole ofnonspecific vesicles being bound when 100 nmole of lipid was incubatedwith the cells. The addition of serum (25 percent fetal calf) duringincubation had no substantial effect on the binding.

The vesicle preparations contained 143 molecues per vesicle, assumingF[ab']₂ has a molecular weight of 90,000 and that the vesiclepreparations contained 1.8×10¹² vesicles per micromole (for unilamellarvesicles of 0.2 μm diameter). Antibodies not purified immunologically,such as those used here, may contain only 1 to 5 percent of moleculesthat are specifically reactive to the cell antigens. The preparationtherefore probably contained approximately one to five specificmolecules per vesicle, so that most vesicles were specific for thetarget cells. The use of nonimmunopurified antibodies with couplingmethod that bind only a few antibody molecules per vesicle would resultin many vesicles having no specificity for the target.

The association of 400 nmole of lipid with 10⁸ human erythrocytesconstitutes a lipid mass three times greater than the lipid content ofthe cell membranes. If one assumes that the vesicles are 0.2 μm indiameter and are unilamellar, the number of vesicles bound per cell is8000 and their encapsulated volume is 0.33 of the cell volume. Thus,about 80% of the targeted vesicles associated with the humanerythrocytes.

The hemagglutinating titre of the F[ab']₂ bound to vesicles was measuredand compared to the original antibody preparation. The nonspecificsoluble F[ab']₂ and the control vesicles derived from it produced nohemagglutination at concentrations up to 1 mg of F[ab']₂ per milliliter.The soluble antibody to human erythrocyte F[ab']₂ had a hemagglutinationtire of 4 μg/ml, and the titre of the liposome-protein conjugatesderived from the original, soluble antibody was 1.5 μg/ml, for animprovement factor of about 2.7.

The extent of improvement, or enhancement, of hemagglutinating activityfor suitable liposome-protein conjugates is greater than appears fromthe data, for example in Table V, since during conjugation some of thebound antibody is partially inactivated. In a further experiment,performed with antifluorescein conjugated liposomes prepared via theactivated method, a variety of antibody preparations were obtained bymixing the immunopurified antifluorescein with normal rabbit IgG to varythe extent of antifluorescein substitution. The activity of theantifluorescein was calculated by fluorescence quenching, as previouslydescribed and illustrated by Table IV, and this value was used tocalculate the number of active antibody molecules per liposome of theliposome-antibody conjugates and the corrected minimum hemagglutinatingconcentration. The liposome-protein conjugates were contacted withunagglutinated erythrocytes which had been coated with fluorescein. (Theuncorrected minimum hemagglutinating concentration (MHC) is calculatedfrom the total protein concentration.) The data is illustrated by TableVI, below.

                  TABLE VI                                                        ______________________________________                                        Active antibody                                                                           MHC      corrected MHC                                                                              Improvement                                 molecules/liposome                                                                        (μg/ml)                                                                             (μg/ml)   factor                                      ______________________________________                                         67         5.10     1.63         2.3                                         100         1.60     0.70         5.6                                         186         0.57     0.31         12.6                                        soluble antibody                                                                          3.90     3.90         --                                          ______________________________________                                    

The improvement factor, illustrated by Table VI, above, compares thecorrected MHC of lipsome-protein conjugates to the MHC of the original,soluble antibody from which the liposome-protein conjugates werederived. As may be seen, the improvement factor varied from about 2.3 toabout 12.6, depending upon the number of active antibody molecules whichwere covalently bound per liposome.

In another preparation of liposome-protein conjugates theliposome-protein conjugates had 50 μg of antihuman erythrocyte Fab'fragments per μmole liposomal phospholipid (about 500 antihuman Fab'fragments per liposome). The precursor liposomes were formed fromPC:cholesterol:PDP-PE and conjugated to Fab' by the procedure of Martinand Papahadjopoulos, J. Biol. Chem., (1981-In Press). The minimumhemagglutinating concentration (MHC) for soluble antibody was 5.2 μg/ml,whereas the MHC for liposome-protein conjugates was 0.17 μg/ml. That is,the agglutination improvement factor was about 30.

Binding Inhibition

Another batch of liposome-protein conjugates via activated liposomeprecursors was prepared and tested with soluble antibody for bindinginhibition as follows.

The precursor liposomes were prepared from a mixture ofphosphatidylcholine:cholesterol:oxidized ganglioside (5:5:1) whichcontained trace amounts of ³ H dipalmioylphosphatidylcholine to give2000 counts per minute (cpm) per nanomole lipid. These vesicles werethen conjugated to monoclonal mouse anti H2K^(k) antibody by reductiveamination with sodium cyanoborohydride. The resultant liposome-proteinconjugates had an antibody:lipid ratio of 60 μmole.

Meanwhile, 5×10⁶ L929 fibroblasts in confluent monolayers in 6 cm petridishes were incubated for 30 minutes at 37° C. with 0.2 ml phosphatebuffered solution (PBS) containing 50% serum and 20 nmole lipid to whichwas conjugated 1.2 μg antibody. The incubation mixture also containedvariable amounts of soluble antibody, as indicated in Table VII, below.After incubation, the cells were washed four times with phosphatebuffered saline, trypsinized to remove them from the monolayer and takenup in scintillant for counting.

In a similar manner, 2×10⁶ R1.1 T-lymphoma cells were suspended in 0.2ml PBS containing 50% serum, 20 nmole lipid conjugated to 1 μg antibodyand various amounts of soluble antibody as indicated in Table VII,below. After 30 minutes they were washed four times by centrifugationand resuspension of the cells in 5 ml portions of PBS. The cells werefinally resuspended in 0.5 ml and taken up in scintillant.

The antibody-anti H2K^(k) reaction which occurred between theliposome-conjugates and the cells (and, to a lesser extent between thesoluble antibody and the cells) illustrates a reaction with the H2K ofcertain mouse strains. This protein is a membrane antigen present athigh levels in most mouse tissues. The L929 fibroblast and the R1.1T-lymphoma are cultured cell lines derived from mice which express theH2K^(k) antigen.

                  TABLE VII                                                       ______________________________________                                        INHIBITION OF TARGETED LIPOSOME BINDING BY                                    SOLUBLE ANTIBODY                                                              Soluble Antibody                                                                              Percent Control Binding                                       Per Sample (μg)                                                                            L929      R1.1                                                ______________________________________                                        0.1             100%      100%                                                0.3             86%       97%                                                 1               97%       81%                                                 3               100%      62%                                                 10              95%       44%                                                 30              66%       31%                                                 ______________________________________                                    

For example, as illustrated by Table VII above, a ratio of soluble toliposome-bound antibody of at least 10:1 was required to achieve about50% binding inhibition with the R1.1 T-lymphoma cells. These datademonstrate that liposome-protein conjugates in accordance with thepresent invention bind with greater functional affinity to theirimmunological partners than does soluble antibody. It is believed this,and the improved agglutination property, is due to a multivalentcharacter of the liposome-protein conjugates, e.g. that each vesiclecontains many antigen binding sites. By contrast, for example, nativeIgG is only bivalent.

A wide variety of proteins particularly antibodies, may be covalentlybound to liposomes and used in accordance with the present invention.Table VIII, below, illustrates a number of liposome-protein conjugatessuitable for immunodiagnostic applications, and particularly for cellagglutinations mediated by combinations with the appropriate antigenicpartner.

                  TABLE VIII                                                      ______________________________________                                                                       antibody to                                    liposome-protein                                                                            bound            lipid ratio                                    conjugate composition #                                                                     antibody         (μg/μmole)                               ______________________________________                                        1             Normal bovine IgG                                                                              100-300                                        2             Normal rabbit IgG                                                                               60-300                                        3             Normal rabbit F[ab'].sub.2                                                                     70                                             4             Rab. antiHRBC F[ab'].sub.2                                                                     60                                             5             Mouse IgG        98                                             6             Rabbit anti CVI  107                                            7             Normal rabbit IgG                                                                              275                                            8             anti sheep RBC (2a)*                                                                           153                                            9             anti H2K.sup.k (2a)*                                                                           72                                             10            anti Thy 1.1 (1)*                                                                              50                                             11            anti sheep RBC (2a)*                                                                           121                                            12            anti H2K.sup.k (2a)*                                                                           70                                             13            Normal human IgG 235                                            14            anti H2K.sup.k (2)*                                                                            52                                             15            Mouse IgG (All)* 128                                            16            anti glycophorin (1)*                                                                          240                                            17            anti sheep RBC (2a)*                                                                           2000                                           ______________________________________                                         (*wherein the symbol within the parentheses gives the IgG subclass of the     antibody)                                                                

Composition numbers 1-10, above, were prepared from precursor liposomesby the activated liposome method (e.g. glycosphingolipids were oxidizedwith periodate and antibody was covalently bound by reductive aminationwith sodium cyanoborohydride). The lipid of compositions 1 and 2 werelactosylceramide, phosphatidylglycerol, phosphatidylcholine andcholesterol in a ratio of 10:3:45:45. The lipid of compositions 3-10consisted of phosphatidylcholine, cholesterol and ganglioside in a ratioof 5:5:1. The antibody of compositions 8-10 was monoclonal (mouse).

Compositions 11 and 12 were prepared from precursor liposomes by apreoxidation modification of the activated liposomes method (e.g.gangliosides were preoxidized, the precursor liposomes were formedtherefrom, and the antibody then conjugated as in the activated liposomemethod). More particularly, gangliosides, usually a mixture from bovinebrain, are suspended in 20 mM sodium-in-periodate at pH 5.5. After 30minutes at room temperature in the dark, ethylene glycol is added to afinal cone of 100 mM and the solution is left 30 minutes. Oxidizedgangliosides are separated from the reaction products by gelchromatography. The ganglioside fractions are pooled, mixed withmethanol and evaporated to dryness under a stream of nitrogen. Theresidue is taken up in chloroform:methanol (1:1) and stored under argonat -40° C. before protein conjugation. Lipid content was as describedfor compositions 3-10, above. The antibody was monoclonal (mouse).

Compositions 13-17 were prepared as follows.N-[4-(p-maleimidophenyl)butyryl]phosphatidylethanolamine (MPB-PE) wassynthesized by the procedure of Martin and Papahadjopoulos, J. Biol.Chem. (1981--In Press). Liposomes are then prepared by the method ofSzoka and Papahadjopoulos, supra, from 10:10:1phosphatidylcholine:cholesterol:MPB-PE in a buffer at pH 6.0-6.7. Asuitable buffer is 0.05M morpholino-ethanesulfonic acid, 0.096M NaCl, pH6.4. It is essential to prepare the vesicle below pH 7.0 to ensure themaximal stability of the maleimide function. The antibody ispyrdiylthiolated and reduced by the method of Carlsson et al. Biochem.J., 173, pp. 723-737 (1978). Reaction of protein with 10 mole ofN-Succinimidyl 3-(2-Pyridyldithio) Proprionate (SPDP) per mole ofprotein results in the substitution of 3-5 mole of pyridyldithiol groupsper mole protein. After reduction with dithiothreitol, the protein isseparated from the reducing agent on a polyacrylamide column (50 to 100mesh) equilibrated in argon-purged (de-oxygenated) buffer, pH 6.0-6.5.The protein fractions are pooled and concentrated to a suitable volumeunder argon in an amicon type concentrator. Commonly, the protein isconcentrated to around 3 mg/μl. Liposomes are then added to the proteinsolution with stirring to give 5 μmole lipid per ml. After reactionovernight, the vesicles are reacted with Aldrithiol 4 and separated on ametrizamide gradient and the protein and lipid are determined.

The protein, or antibody, was modified in compositions 13-17 by fromabout 1.8 to about 5.1 thiols per molecule.

Industrial Applicability

The enhanced agglutination activity of liposome-protein conjugates isuseful for a variety of diagnostic applications, such as in inhibitionassays and flocculation tests. Hemagglutin inhibition assays measure theextent to which a soluble antigen inhibits the capacity of its specificantibody to agglutinate antigen-sensitized erythrocytes.Liposome-protein conjugates can increase the sensitivity ofhemagglutination inhibition assays. Since considerably less antibody isrequired for agglutination, a correspondingly less amount of solubleantigen will inhibit agglutination. That is, soluble antigen willcompete with an erythrocyte surface antigen of the same antigenicspecificity, and thus the presence of soluble antigen will reduce theamount of agglutination produced by liposome-protein conjugates specificfor the antigen. One may thus determine the extent to which the solubleantigen inhibits cell agglutination mediated by antibody-antigeninteraction. Among the human serum antigens which may be detected by themore sensitive liposome-protein conjugates are peptide hormones, such asthyroxin, C-reactive protein, hepatitis surface antigen, hCG,heterophile antibodies, rheumatoid antibodies, thyroxin binding protein(T₃) and digoxin.

In addition, liposome-protein conjugates may be used in flocculationtests. For example, where the liposome-protein conjugates have anantibody covalently bound to the liposomes, the antibody may be selectedwith an antigen binding capacity for a particle such as the Daneparticle of hepatitis B virus, which would be more sensitivelyflocculated, or agglutinated, when contacted with the liposome-proteinconjugates than when contacted with the original antibody from which theconjugates are derived.

The best mode contemplated for carrying out the present invention is useof liposome-protein conjugates in blood typing. The preferred size ofliposomes for such use is from about 0.1 micron to about 5 micron, andmore preferred from about 0.1 to about 0.5 micron.

The size is most preferably controlled by extrusion through straightpore polycarbonate filters, as is described in U.S. Pat. No. 4,263,428,issued Apr. 21, 1981. The extrusion permits the production of uniformvesicles in selected sizes between about 0.1 and about 0.5 micron.

The antibody preparation is covalently bound to the liposome so that theantibody is in an amount of at least about 40 microgram per micromole oflipid molecules, more preferably from about 40 to about 90 microgram permicromole of lipid. The antibody may be derived from a normal polyclonalantiserum, or from a monoclonal antibody. The liposome-proteinconjugates are then separated from the soluble, unbound antibody byflotation in a discontinuous metrizamide gradient. The recoveredliposome-protein conjugates may then be analyzed for protein and lipidcontent.

To establish the minimum quantity of the liposome-protein conjugatesrequired for agglutination, serial two-fold dilutions of theliposome-protein conjugates are prepared in a hemagglutination plate(e.g. one half, one quarter, one eighth, one sixteenth, etc.). Thesedilutions are then mixed with an equal volume of a 2% erythrocytesuspension and left to stand for about 18 hours. The wells are thenscored for agglutination, and the most dilute solution which givesagglutination is taken to be the minimum hemagglutination concentration.

Liposome-protein conjugates at a concentration known to giveagglutination of antigen-positive cells are then mixed with erythrocyteswhose expression of the antigen is to be determined. After incubationfor a suitable period, the cells are scored for agglutination.

While the invention has been described in connection with specificembodiments thereof, it will be understood that it is capable of furthermodification, and this application is intended to cover any variations,uses or adaptations of the invention following in general, theprinciples of the invention and including such departures from thepresent disclosure as come within known or customary practice in the artto which the invention pertains and as may be applied to the essentialfeatures hereinbefore set forth, and as fall within the scope of theinvention and the limits of the appended claims.

We claim:
 1. A reagent, useful for hemagglutination assays,comprising:conjugates comprising (a) liposomes and (b) antibodycovalently bound to the liposomes, the liposomes having lipid molecules,the covalently bound antibody having an antigen binding capacity forerythrocytes, said erythrocytes bearing a surface antigen for which thecovalently bound antibody is specific, to mediate hemagglutination viaantigen-antibody interaction, the covalently bound antibody being in anamount of at least about 40 micrograms per micromole of lipid molecules,the conjugates having an enhanced hemagglutinating activity with respectto the hemagglutinating activity of antibody from which the conjugatesare derived.
 2. The reagent of claim 1 wherein:the covalently boundantibody is derived from a polyclonal antiserum or is a monoclonalantibody, and the hemagglutinating activity is determinable as a minimumhemagglutinating concentration.
 3. The reagent as in claim 1 wherein:theenhanced hemagglutinating activity is at least about 1.5 times greaterthan the hemagglutinating activity of antibody from which the conjugatesare derived.
 4. The reagent as in claim 1 wherein:the liposomes of theconjugates are from about 0.1 micron to about 5 micron in size.
 5. Thereagent as in claim 1 wherein:the liposomes are a substantially uniformsize between about 0.1 and about 0.5 microns.
 6. The reagent as in claim1 wherein:the covalently bound antibody is IgG or a fragment thereof. 7.The reagent as in claim 6 wherein:the IgG or fragment thereof is in anamount of from about 40 micrograms to about 90 micrograms per micromoleof lipid molecule.
 8. A reagent, useful for cell agglutination assays,comprising:conjugates comprising (a) liposomes and (b) antibodycovalently bound to the liposomes, the liposomes having lipid molecules,the covalently bound antibody having an antigen binding capacity forcells, said cells bearing a cell surface antigen for which thecovalently bound antibody is specific, to mediate agglutination viaantigen-antibody interaction, the covalently bound antibody being in anamount of at least about 40 micrograms per micromole of lipid molecules,the conjugates having an enhanced agglutinating activity with respect tothe agglutinating activity of antibody from which the conjugates arederived.
 9. The reagent of claim 8 wherein:the covalently bound antibodyis derived from a polyclonal antiserum or is a monoclonal antibody. 10.The reagent as in claim 8 wherein:the liposomes of the conjugates arefrom about 0.1 micron to about 5 microns in size.
 11. The reagent as inclaim 8 wherein:the liposomes are a substantially uniform size betweenabout 0.1 and about 0.5 microns.
 12. The reagent as in claim 8wherein:the covalently bound antibody is IgG or a fragment thereof. 13.The reagent as in claim 8 wherein the cells include fibroblasts orlymphocytes.
 14. The reagent as in claim 8 wherein the covalently boundantibody includes IgG or Fab fragments which are attached to the lipidmolecules of the liposomes through disulfide bonds.